Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions

被引：4

作者：

Fuchs, EJ ^{[1
]}

Seber, A ^{[1
]}

Altomonte, V ^{[1
]}

Braine, HG ^{[1
]}

Humphrey, RL ^{[1
]}

Jones, RJ ^{[1
]}

Noga, SJ ^{[1
]}

Schepers, K ^{[1
]}

Wright, SK ^{[1
]}

Vogelsang, GB ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med,Bone Marrow Transplantat Program, Johns Hopkins Oncol Ctr, Div Hematol Malignancies, Baltimore, MD 21205 USA

来源：

BONE MARROW TRANSPLANTATION | 1998年 / 22卷 / 03期

关键词：

multiple myeloma; bone marrow transplantation; leukocyte transfusions; chemotherapy; graft-versus-myeloma; graft-versus-host disease;

D O I：

10.1038/sj.bmt.1701323

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Two patients with multiple myeloma in relapse after allogeneic BMT received donor lymphocyte infusions (DLI) but later required chemotherapy for treatment of myeloma-related complications. In both patients, recovery from chemotherapy-induced aplasia was accompanied by manifestations of graft-versus-host reactions. The first patient developed grade II acute GVHD and a complete remission which has lasted >22 months. The second patient developed grade III acute GVHD but died with co-existing GVHD and extensive extramedullary myeloma, These results demonstrate that chemotherapy does not nullify the ability of donor lymphocytes to mediate graft-versus-host reactions.

引用

收藏

页码：303 / 305

页数：3

相关论文

共 11 条

[1]

BUTTURINI A, 1986, BLOOD, V68, P954

[2] Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].

Collins, RH ;

Shpilberg, O ;

Drobyski, WR ;

Porter, DL ;

Giralt, S ;

Champlin, R ;

Goodman, SA ;

Wolff, SN ;

Hu, W ;

Verfaillie, C ;

List, A ;

Dalton, W ;

Ognoskie, N ;

Chetrit, A ;

Antin, JH ;

Nemunaitis, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444

[3] GRAFT-VERSUS-LEUKEMIA EFFECT OF DONOR LYMPHOCYTE TRANSFUSIONS IN MARROW GRAFTED PATIENTS [J].

KOLB, HJ ;

SCHATTENBERG, A ;

GOLDMAN, JM ;

HERTENSTEIN, B ;

JACOBSEN, N ;

ARCESE, W ;

LJUNGMAN, P ;

FERRANT, A ;

VERDONCK, L ;

NIEDERWIESER, D ;

VANRHEE, F ;

MITTERMUELLER, J ;

DEWITTE, T ;

HOLLER, E ;

ANSARI, H .

BLOOD, 1995, 86 (05) :2041-2050

[4] Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation [J].

Lokhorst, HM ;

Schattenberg, A ;

Cornelissen, JJ ;

Thomas, LLM ;

Verdonck, LF .

BLOOD, 1997, 90 (10) :4206-4211

[5] ADOPTIVE IMMUNOTHERAPY EVALUATING ESCALATING DOSES OF DONOR LEUKOCYTES FOR RELAPSE OF CHRONIC MYELOID-LEUKEMIA AFTER BONE-MARROW TRANSPLANTATION - SEPARATION OF GRAFT-VERSUS-LEUKEMIA RESPONSES FROM GRAFT-VERSUS-HOST DISEASE [J].

MACKINNON, S ;

PAPADOPOULOS, EB ;

CARABASI, MH ;

REICH, L ;

COLLINS, NH ;

BOULAD, F ;

CASTROMALASPINA, H ;

CHILDS, BH ;

GILLIO, AP ;

KERNAN, NA ;

SMALL, TN ;

YOUNG, JW ;

OREILLY, RJ .

BLOOD, 1995, 86 (04) :1261-1268

[6] RELAPSE OF ACUTE-LEUKEMIA AFTER MARROW TRANSPLANTATION - NATURAL-HISTORY AND RESULTS OF SUBSEQUENT THERAPY [J].

MORTIMER, J ;

BLINDER, MA ;

SCHULMAN, S ;

APPELBAUM, FR ;

BUCKNER, CD ;

CLIFT, RA ;

SANDERS, JE ;

STORB, R ;

THOMAS, ED .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :50-57

[7] CD34(+) stem cell augmentation of allogeneic, elutriated marrow grafts improves engraftment but cyclosporine a is still required to reduce GVHD and morbidity [J].

Noga, SJ ;

Vogelsang, GB ;

Seber, A ;

Davis, JM ;

Schepers, K ;

Hess, AD ;

Jones, RJ .

TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) :728-732

[8]

Porter D., 1997, Blood, V90, p384B

[9]

STORB R, 1971, J IMMUNOL, V107, P409

[10] MARROW TRANSPLANTATION FOR TREATMENT OF APLASTIC-ANEMIA - ANALYSIS OF FACTORS ASSOCIATED WITH GRAFT REJECTION [J].

STORB, R ;

PRENTICE, RL ;

THOMAS, ED .

NEW ENGLAND JOURNAL OF MEDICINE, 1977, 296 (02) :61-66